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Abstract
Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and one of the most aggressive 
cancers in man. Despite technological advances in surgical management, combined regimens of radiotherapy with 
new generation chemotherapy, the median survival for these patients is 14.6 months. This is largely due to a highly 
deregulated tumour genome with opportunistic deletion of tumour suppressor genes, amplification and/or 
mutational hyper-activation of receptor tyrosine kinase receptors. The net result of these genetic changes is 
augmented survival pathways and systematic defects in the apoptosis signalling machinery. The only randomised, 
controlled phase II trial conducted targeting the epidermal growth factor receptor (EGFR) signalling with the small 
molecule inhibitor, erlotinib, has showed no therapeutic benefit. Survival signalling and apoptosis resistance in GBMs 
can be viewed as two sides of the same coin. Targeting increased survival is unlikely to be efficacious without at the 
same time targeting apoptosis resistance. We have critically reviewed the literature regarding survival and apoptosis 
signalling in GBM, and highlighted experimental, preclinical and recent clinical trials attempting to target these 
pathways. Combined therapies simultaneously targeting apoptosis and survival signalling defects might shift the 
balance from tumour growth stasis to cytotoxic therapeutic responses that might be associated with greater 
therapeutic benefits.
Background
The process by which a normal cell transforms and devel-
ops into a malignant tumour requires several cellular
alterations [1]. Evasion of apoptosis is a hallmark of most,
if not all cancers, because defects in its regulators invari-
ably accompany tumourigenesis and sustain malignant
progression. Many anticancer agents aim to induce apop-
tosis, and so its disruption during tumour evolution can
promote drug resistance and subsequent therapy failure.
Survival signalling is distinct from apoptosis resistance
and rescues cancer cells from death following otherwise
lethal DNA damage. Since both apoptosis resistance and
increased survival signalling are major regulators of can-
cer cell survival, targeting only one of these compart-
ments may not be sufficient to obtain therapeutic effects.
Glioblastoma multiforme (GBM) is the most common
and malignant subset of brain tumours, classified as
grade IV astrocytoma by the World Health Organisation
(WHO) [2]. Standard first line treatment for glioblastoma
patients includes surgery followed by focal fractionated
radiotherapy with concomitant and adjuvant administra-
tion of the alkylating chemotherapy, temozolomide [3].
The addition of temozolomide significantly improves the
median, 2- and 5-year survival compared to radiotherapy
alone in patients with newly diagnosed glioblastoma
[4,5]. Nevertheless, glioblastoma patients have a poor
prognosis with a median survival of 14.6 months [5]. A
recognized predictor for tumour response to temozolo-
mide is the epigenetic silencing of the O6-methylguanine-
DNA-methyltransferase (MGMT) gene promoter by
methylation [6]. The ubiquitous DNA repair protein
MGMT counteracts chemotherapy-induced DNA dam-
age by restoring the structural integrity of O6-alkylated
bases. Around half of all glioblastoma patients harbour an
unmethylated MGMT promoter, and these seem to
respond poorly to temozolomide chemotherapy [7]. To
date there is no alternative treatment for this group.
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survival and apoptosis resistance will enable us to exploit
the key players to design smarter drug combinations in
targeted cancer therapies.
Genetic characteristics of GBMs
GBMs are characterised by high inter- and intra-
tumoural morphological and lineage heterogeneity, hence
the moniker "multiforme". They have been traditionally
defined as two clinically and cytogenetically distinct dis-
eases, the primary or de novo versus the secondary
GBMs. The latter classically afflict younger persons
(median age ~45 years) and evolve from the slow progres-
sion (mean, 4-5 years) of a low-grade glioma and pos-
sesses aberrations in platelet derived growth factor
receptor (PDGFR) and TP53 genes. Recently, mutations
in the active site of isocitrate dehydrogenase 1 (IDH1)
gene was identified in a large fraction of young patients as
well as those with secondary GBMs, and correlated with
increased overall survival [8,9]. In contrast, primary
GBMs present acutely (with a clinical history less than 6
months) as a high-grade disease that most frequently
affects the elderly (median age ~60 years) and typically
harbours mutations in epidermal growth factor receptor
(EGFR), cyclin-dependent kinase inhibitor 2A (CDKN2A)
and loss of heterozygosity (LOH) on chromosome 10q23,
which houses the phosphatase and tensin homolog
(PTEN) gene. LOH on chromosome 10 is the most fre-
quent genetic alteration in primary GBMs, occurring in
60-80% of cases [10]. However, this distinction of mutu-
ally exclusive GBM subtypes based on TP53 mutation
and EGFR amplification [11-13] has been challenged [14].
A recent integrated genome analysis performed in 22
GBM and verified in 83 patient GBMs revealed that
amongst the most frequently altered genes were TP53
(40%); EGFR (37%); PTEN (30%) [8]. However, the initial
screen of 22 GBMs included only 7 primary human biop-
sies, while 15 had been passaged in nude mice as xeno-
grafts. Other studies have cited that between 40-60% of
GBMs show EGFR amplification and protein overexpres-
sion and that approximately 40% of GBMs with EGFR
amplification also harbour EGFR mutations [15]. These
display a mutant EGFR variant with loss of the extracellu-
lar, ligand-binding domain, coded for by genes in exons 2-
7 (EGFRvIII). This mutation results in ligand indepen-
dent constitutive tyrosine kinase activity that activates
persistent downstream RAS/RAF/MAPK growth and
PI3K survival signalling [15]. However, the prognostic
value of either TP53 mutations or EGFR alterations has
been elusive [16,17]. Indeed, in a study of 67 GBM patient
biopsies, no association between EGFR and PDGFR
amplification nor TP53 mutation and patient survival was
observed [18]. Despite the differing cytogenetic aberra-
tions, the resulting histopathological lesion is one that
culminates in GBM as the common phenotypic endpoint
with similar resistance patterns and survival outcome.
Survival signalling in glioblastomas
Phosphtaidylionositol-3-kinase signalling -Receptor 
Tyrosine Kinase cross talk
Survival signalling allows the cell to overcome stressful or
deleterious environments by inducing expression or
availability of survival factors. The class IA phosphtaidy-
lionositol-3-kinase (PI3Ks) are activated by receptor
tyrosine kinases (RTKs) and are highly implicated in can-
cer cell survival [19]. EGFRs and PDGFRs are the most
common RTKs with intrinsic tyrosine kinase activity that
are aberrantly expressed in GBMs. PI3K is translocated to
the plasma membrane through binding to phosphoty-
rosine residues on RTKs. Activated PI3K produce phos-
phatidylinositol-3,4,5 triphosphate (PIP3) from the
substrate phosphatidylionositol-3,4 diphosphate (PIP2),
Figure 1 Survival Signalling. Hyperactive Receptor tyrosine kinases 
in GBMs, e.g., EGFR, PDGFR signal upon ligand binding or constitutive 
activation via Ras-MEK-ERK to mediate cell growth and angiogenesis 
and via PI3K/AKT to mediate survival. AKT phosphorylates multiple 
substrates that lead to release of survival factors or interference with 
the execution of apoptosis. Phosphoinositide-dependent kinase 1 
(PDK1), phosphatidylinositol-3,4,5 triphosphate (PIP3), phosphoinosit-
ide-4,5 bisphosphate (PIP2), pro-apoptotic BCL-2-associated agonist of 
cell death (BAD), and Nuclear factor κB (NFκB).
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inositide-dependent kinase 1 (PDK1) and AKT to the
plasma membrane. AKT is activated through phosphory-
lation at two key regulatory sites, Thr308 (by PDK1) and
Ser473 (by mTOR complex 2). Activated AKT subse-
quently promotes survival by facilitating nuclear translo-
cation of nuclear factor κB (NFκB) which then
transcriptionally activates multiple genes that mediate
cell survival and drive proliferation [20]. An immunohis-
tochemistry study of 70 GBMs on a tissue micro-array
reported that 91.3% of the GBMs samples possessed acti-
vated NFκB that was highly correlated with activated
AKT levels [21].
PTEN functions as a tumour suppressor that negatively
regulates PI3K activity by dephosphorylating PIP3 to PIP2
and thereby terminating PI3K signalling [22], Figure 1.
Mutations of the PTEN gene in GBMs result in elevated
levels of PIP3, through which PI3K hyperphosphorylates
PDK1/AKT [23]. The p110α subunit of PI3K is encoded
by PIK3CA gene, and somatic nucleotide substitutions in
this gene were detected in 6 of the 91 GBM samples
sequenced. Some of these deletions imposed spatial con-
straints that might result in PI3K constitutive activation
[24]. The regulatory p85α subunit of PI3K is encoded by
PIK3R1 gene. Constitutive activating mutations in this
subunit were identified in 9 of 91 GBMs [24]. Interest-
ingly, in these GBMs it appears that PIK3CA and PIK3R1
mutations were mutually exclusive, suggesting a func-
tional redundancy of these mutations as they both acti-
vate PI3K. PIK3CA and PIK3R1 genes were
independently reported altered in 8-10% of GBM cases
[8]. A somatic mutation in the coding sequence of the
AKT1 gene previously identified in breast, ovarian and
colon cancers could not be identified in a panel of 109
GBM samples and 9 high-grade astrocytoma cell lines
[25], indicating that AKT activation in GBMs was not
mediated by this activating mutation. While the prognos-
tic value of genetic changes in the PI3K subunits is not
elucidated, studies have shown that losses on chromo-
some 10, i.e. loss of the PTEN locus, or enhanced PI3K
signalling are associated with poor outcome in GBM [26].
The median survival of GBM patients with activated
PI3K (n = 42/56) and AKT (37/56) was 11 months com-
pared to 40 months in patients with lower activation lev-
els of PI3K and AKT [26]. Despite receiving only partial
surgical resection, and adjuvant radiotherapy, the
patients with diminished PI3K and AKT activation had
an astonishingly high median survival of 40 months.
PI3K-mTOR crosstalk
Activated AKT phosphorylates and inactivates tuberous
sclerosis 2 (TSC2), a GTPase-activating protein for Ras
homologue enriched in brain (RHEB), see Figure 2. Inac-
tivation of TSC2 allows RHEB to accumulate in the GTP-
bound state and thus activate the seine-threonine kinase
mTORC1. mTORC1 is a complex of mTOR with Raptor,
LST8 and AKT1 substrate. mTORC1 phosphorylates
p70S6kinase and 4E-binding protein 1 (4EBP1), 4EBP2
and 4EBP3 and leads to translation of mRNAs that
encode many cell cycle regulators such as MYC, cyclin
D1, hypoxia inducible factor alpha (HIF1α), subsequently
leading to proliferation and angiogenesis. Levels of
p70S6kinase have been shown to predispose to poor out-
comes in GBM patients [26], where the median survival
was 10 months compared to 40 months in patients with
attenuated p70S6kinase levels. Increased activity of
mTOR has been detected in GBMs with constitutively
active EGFR and low PTEN activity. mTORC1 complex is
effectively inhibited by rapamycin and its analogues.
PI3K-Ras crosstalk
The PI3K/AKT signalling cascade crosstalks with the
mitogen activated protein-kinase (MAPK) via Ras, a
membrane bound G-protein that initiates signalling
downstream from activated RTKs such as EGFR or
PDGFR. Receptor induced Ras activation is a common
feature of GBMs [27]. Constitutive activation or ligand-
binding of EGF or PDGF to these receptors leads to auto-
phosphorylation of intracellular tyrosine residues and
Figure 2 PI3K crosstalks with MEK and mTOR pathways. In addi-
tion to their divergent signalling cascades, these pathways converge 
on mTOR and drive a negative feedback loop on AKT regulation. For 
GBMs, combined PI3K/AKT and Raf-MEK-ERK inhibition might be re-
quired to shutdown mTORC1 signalling and promote apoptosis, au-
tophagy and prevent cell growth. Tuberosclerosis 1 (TSC1 and 2); 
Tumour necrosis factor alpha (TNFα), hypoxia inducible factor (HIF1α), 
regulated in development and DNA damage response 1 (REDD1), 4E-
binding protein (4EBP).
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[28]. Activation of Ras recruits Raf to the cell membrane
[29] and subsequent phosphorylation of tyrosine or ser-
ine/threonine residues by Src kinases or PKC, respec-
tively [30], Figure 1. This initiates a signalling cascade
downstream via the MAPKs and ERK-1 and 2 kinases,
which then activate cytoplasmic targets such as p90RSK.
This serine/threonine kinase [31] translocates to the
nucleus where it activates transcription factors including
IκB/NFκB and cyclic AMP response element binding
protein (CREB) that regulate glioma cell survival and pro-
liferation [32], respectively [33]. PI3K/AKT and Ras/
MAPK are thus important cellular survival and growth
signalling pathways that are constitutively activated in
tumours harbouring mutations in PTEN and genetic
aberrations in growth factor receptors.
Targeting PI3K/AKT signalling in GBM
EGFR Inhibitors
Two small molecule EGFR tyrosine kinase inhibitors have
been developed, erlotinib (Tarceva®, OSI-774, Genentech,
Inc, CA, USA) and gefitinib (Iressa®, ZD1839, AstraZen-
eca, DE, USA) that have been evaluated for GBM treat-
ment, Table 1. However, monotherapy with neither drug
had a clear benefit of prolonged survival. A randomised,
controlled phase II study by the European Organisation
for Research and Treatment of Cancer (EORTC) failed to
show improved radiographic responses or survival bene-
fit of erlotinib. The progression free survival (PFS) was
11.4% for erlotinib versus 24% (temozolomide/carmus-
tine) in 110 patients with progressive GBM [34]. It has
previously been reported that GBM patients exhibiting
amplification or over-expression of EGFR responded bet-
ter to erlotinib than patients with normal EGFR levels
[35]. The response was however, highly dependent on low
levels of AKT activation. This is supported by the finding
that co-expression of wild-type (wt) PTEN with EGFRvIII
predicted radiographic responses in patients treated with
gefitinib or erlotinib [36], indicating that when AKT
phosphorylation is a direct result of increased EGFR
activity, treatment with EGFR inhibitors might result in
better clinical responses. However, the EORTC study [34]
found neither the expression of EGFR, EGFRvIII nor
PTEN to be correlated with a survival advantage, and
actually both progression free survival and overall sur-
vival was worse for the patients exhibiting EGFRvIII
treated with erlotinib. The association of particular muta-
tions in the EGFR kinase regions with improved clinical
and radiographic responses after gefitinib treatment pre-
viously reported in lung cancer patients [37] has not been
demonstrated in GBM patients [38]. However, a phase I
study of 83 glioma patients treated with either erlotinib
alone or in combination with temozolomide, showed that
5 GBM patients (median age 50.2 years) had stable dis-
ease that lasted longer than 12 weeks (4 treated with erlo-
tinib alone and 1 treated with erlotinib in combination
with temozolomide). Of these patients 3 had PFS greater
than 6 months [39]. A small phase II, single institution
study of erlotinib plus temozolmide before and after radi-
ation in 65 patients with newly diagnosed GBM and
gliosarcoma and stratified for MGMT promoter methyla-
tion, showed an increased median survival of 19.3
months compared to 14.1 months of historical controls
[40]. They found a survival benefit for patients whose
tumours were both MGMT promoter hypermethylated
and PTEN positive indicating that lack of survival signal-
ling benefits therapy response in the absence of DNA
repair. Another phase I/II study (N0177) comparing erlo-
tinib combined with temozolomide and radiotherapy for
97 newly diagnosed GBM patients achieved no additional
benefit for erlotinib in the combination compared to his-
torical, EORTC 26981 as control studies [41]. Similarly, A
phase II study of 27 GBM patients receiving similar doses
of erlotinib in combination with radiotherapy and temo-
zolomide had to be terminated prematurely after accrual
of 27 of 30 patients due to lack of efficacy and unaccept-
able toxicity [42]. Sources of discrepancies among these
studies include technical variability of EGFR biomarker
assessment. In many studies, biopsy samples obtained at
the time of primary surgery are used to characterise
EGFR levels but the molecular characteristics of the
tumour after recurrence are not always the same. Unfor-
tunately, it is often not feasible to obtain new biopsies
from recurrent GBM patients, rendering this a persistent
challenge in targeted therapies. Although EGFR is impor-
tant for activation of PI3K/AKT, numerous other RTK are
co-activated in GBM cells [43], [44], [45] and treatment
with single tyrosine kinase inhibitors like erlotinib may
not be sufficient to decrease survival signalling. It has
been demonstrated that PDGFR and c-MET receptors
are engaged after EGFR inhibition and maintain down-
stream pathway activation [46]. This suggests that care-
fully designed inhibitor combinations with limited
toxicity profiles and maximal additive or synergistic
effects may provide more beneficial therapeutic effects
[47]. Another source for antagonism is that EGFR inhibi-
tors cause G1 cell cycle arrest, making cells less sensitive
to the cell cycle dependent effects of radiotherapy and
temozolomide. Temozolomide causes cell cycle arrest in
G2-M [48], so erlotinib and gefitinib prevent cells from
progressing beyond G1 and may therefore compromise
the activity of other cell cycle-specific agents. The
EORTC study [34] included a randomised control arm of
patients treated with either BCNU or temozolomide that
allowed the distinction between prognostic and predic-
tive markers for outcome. It has been suggested that the
association between increased progression free survival
and EGFR molecular characteristics may simply reflect
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Table 1: Summary of clinical trials targeting survival and apoptosis pathways in GBM
Target Drug (s) Trial design Study population Outcome Ref
EGFR Erlotinib Randomised, controlled, 
phase II #26032
110 Recurrent GBM 6-month PFS: 11.4% vs 24% 
control, Low akt borderline 
significance
[34]
Erlotinib (+RT+TMZ) Phase I/II cf historical controls 
#N0177
97 newly diagnosed GBM Median survival 15.3 months, no 
benefit at OS
[41]
Erlotinib (+RT +TMZ) Phase II cf historical controls 65 newly diagnosed GBM/
gliosarcoma
Median survival 19.3 months vs 
14.1 controls, positive correlation 
MGMT methylation with survival 
and MGMT methylation + PTEN 
positivity with improved survival
[40]
Erlotinib (+RT +TMZ) Phase II 27 newly diagnosed GBM OS 8.6 months median PFS 2.8 
months
[42]
Erlotinib (+RT+TMZ) Phase II #NCT00187486 Newly diagnosed GBM/
gliosarcoma
Ongoing http://
www.clinicaltrials.gov
Erlotinib single-agent Phase II open-label, 
multicenter #NCT00337883
First Relapse GBM Completed http://
www.clinicaltrials.gov
Gefitinib Phase II 53 Recurrent GBM 31 patients had radiographic 
progressive disease within the first 
2 months, 51 progressed 
eventually median EFS: 8.1 weeks
[53]
Erlotinib +RT+TMZ) Phase II #NCT00274833 Newly diagnosed GBM Ongoing http://
www.clinicaltrials.gov
Akt Perifosine Phase II #NCT00590954 Recurrent/progressive 
Malignant Gliomas
Ongoing http://
www.clinicaltrials.gov
Perifosine and 
Temsirolimus
Phase I/II #NCT01051557 Recurrent/progressive 
Malignant Glioma
Planned, not yet recruiting http://
www.clinicaltrials.gov
Nelfinavir (+TMZ +RT) Phase I/II #NCT00694837 Newly diagnosed GBM Recruiting http://
www.clinicaltrials.gov
PI3K/mTOR XL765 +TMZ Phase I #NCT00704080 Adults Malignant Gliomas
mTOR Temsirolimus (CCI-779) Phase II 65 Recurrent GBM 6-month PFS: 7.8% median OS 4.4 
months, high levels phospho 
p70s6K appear to predict benefit 
of treatment
[60]
Temsirolimus Phase II 43 Recurrent GBM No evidence of efficacy, 1 patient 
PF at 6-month: 2 PR, 20 SD, median 
time to progression 9 weeks
[59]
Temsirolimus 
(+TMZ+RT)
Phase I #NCT00316849 newly diagnosed GBM Recruiting http://
www.clinicaltrials.gov
Temsirolimus (+ 
Erlotinib+ Tipifarnib)
Phase I/II #NCT00335764 recurrent GBM/
gliosarcoma.
Recruiting http://
www.clinicaltrials.gov
Everolimus + gefitinib Phase I/II #NCT00085566 Progressive GBM Ongoing http://
www.clinicaltrials.gov
Everolimus Phase I/II Pilot, Multicenter 
#NCT00515086
Recurrent GBM Completed, Decemeber 2009
Everolimus +AEE788 Phase IB/II multicenter, two-
Arm, dose-escalation
Recurrent GBM Ongoing http://
www.clinicaltrials.gov
Bcl-2 Gossypol Phase II #NCT00540722 Recurrent GBM Ongoing http://
www.clinicaltrials.gov
Gossypol (AT-101) +RT 
+TMZ vs AT-101 
+Adjuvant TMZ
Phase I non-randomised 
#NCT00390403
Newly diagnosed GBM Completed, June 2009
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mutations [49]. The low molecular weights of these
inhibitors should enable them to cross the blood brain
barrier, however they do so in insufficient concentrations
and this may be a further source of variation in the stud-
ies [50,51]. Both gefitinib and erlotinib are metabolised
by CYP3A4 enzymes and drug levels determined by phar-
macokinetic measures drop significantly in patients tak-
ing enzyme-inducing anti-epileptics (EIAEDs). Although
the low toxicity observed suggests that greater doses may
be tolerated, it may be difficult to standardise the
amounts of active drug in these patients Surrogate mark-
ers of systemic anti-EGFR activity such as development of
rash or diarrhoea do not define activity in the tumour, but
may represent a minimal level of activity and have been
correlated with treatment response in some trials
[34,52,53]. However, the lack of availability of tumour tis-
sue post treatment for validation of target inhibition
results in uncertainties regarding the sufficient inhibition
of the EGFR signalling.
AKT Inhibitors
Several inhibitors of the PI3K/AKT pathway have been
developed, and some are in the early phases of clinical tri-
als, Table 1. Perifosine (Keryx Biopharmaceuticals, NY,
USA), an oral inhibitor of AKT/MAPK has been demon-
strated to effectively reduce tumour growth in a genetic
mouse glioma model [54]. However, the tumours utilised
in this sensitive preclinical model were of an oligoden-
droglial histology and not a GBM. Human oligodendro-
gliomas are generally more sensitive to chemotherapy
than GBMs due to genetic alterations on chromosome 1p
and 19q [55,56]. Despite this, monotherapy with perifos-
ine or in combination with temozolomide primarily pro-
moted tumour growth arrest in vivo, as substantial
numbers of tumour cells were evident in histological sec-
tions of treated animals. A phase II clinical trial of peri-
fosine in recurrent or progressive malignant glioma is in
progress, Trial #NCT00590954 http://clinicaltrials.gov.
In addition, 3 phase I trials are currently recruiting
patients diagnosed with GBM for treatment studies of
radio- and/or chemotherapy combined with nelfinavir, a
protease inhibitor that interferes with AKT activity [57]
downstream of EGFR, Trial #s NCT00915694,
NCT01020292, NCT00694837 http://clinicaltrials.gov.
mTOR Inhibitors
Several mTOR small molecule inhibitors have been devel-
oped, including rapamycin (sirolimus™ or Rapamune®
produced by Wyeth, PA, USA), everolimus™ (RAD001,
structurally related to rapamycin, produced by Norvatis,
NJ, USA) and deforolimus™ (AP23573, produced by Ariad
Pharmaceuticals, Cambridge, MA, USA). These agents
are lipophilic, show good blood brain barrier penetration
[58] and have been evaluated in clinical trials for GBM.
Phase II studies of temsirolimus as monotherapy in
recurrent GBM from two independent studies demon-
strated low toxicity but limited efficacy with response
rates of 10-15% patients and no significant prolongation
of survival [59,60]. This may be due to the fact that
mTOR monotherapies only abrogate the mTORC1 com-
plex and not mTORC2, which is involved in tumour cell
invasion. In addition, mTORC1 inhibition by rapamycin
and its analogues often leads to negative feedback hyper-
activation of PI3K/AKT [61], thus limiting the therapeu-
tic effects, and depending on the mutations in the
tumours, possibly creating a more aggressive phenotype.
Although dual-PI3K-mTOR inhibitors such as PI-103,
might mitigate these partial effects [62], their effects on
simultaneous mTORC-1 and -2 inhibition in normal cells
is uncertain. These dual inhibitors may effectively shut-
down PI3K/AKT signalling in cancers with PIK3CA and/
or PIK3R1 mutations, PTEN loss, and RTK-dependent
activation, all features that embody a large number of
GBMs. A phase I study sponsored by Exelixis is currently
recruiting GBM and anaplastic glioma patients to exam-
ine the safety, toxicity, and maximum tolerated dose of
XL765, dual-PI3K-mTOR capsules administered in com-
bination with temozolomide, trial # NCT00704080, http:/
/clinicaltrials.gov.
Combination Targeting
Several clinical trials are investigating combination tar-
geting of intracellular effectors in the EGFR and PI3K/
AKT pathways in an attempt to both target tumour
growth and circumvent possible resistance mechanisms,
Table 1. A preclinical study combining a tyrosine kinase
inhibitor, AEE788, (Norvartis Pharma, Basel Switzerland)
with everolimus™ demonstrated reduced proliferation,
cell cycle arrest and apoptosis in vitro [63]. In vivo they
demonstrated greater tumour growth inhibition and
improved median survival compared to monotherapy.
However, results based on these subcutaneous xenograft
models may not be predictive of the therapeutic efficacy
of these agents given the challenges of efficient drug
delivery to the patient brain. Others studied the in vitro
synergistic anti-tumour effects after combined EKI-785
(EGFR inhibitor) with rapamycin on glioma cell lines
[64]. In this study, single agent inhibition of EGFR was
associated with accumulation of EGFR at the plasma
membrane, decreased inhibitory 4EBP1/elF4E interac-
tion and translation of complex 5'UTR-containing tran-
scripts that drive cell proliferation and angiogenesis [64].
However, combination treatment with EKI-785 and
rapamycin promoted maximal 4EBP1/elF4E binding that
likely contributed to the synergistic effects of combined
mTOR-EGFR targeted therapy. Erlotinib has been com-
bined with the dual-PI3K-mTOR inhibitor, PI-103, and
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to monotherapy or erlotinib with either PI3K inhibitor or
mTOR inhibitor [62]. Despite the blockade of PI3K,
EGFR and mTOR with efficient AKT inhibition, little
apoptosis of the tumour cells was detected, again empha-
sizing the need to induce cytotoxic rather than cytostatic
therapeutic responses. In clinical trials, erlotinib and
gefitinb have been combined with either sirolimus or
everolimus, and AEE-788 with everolimus [65,66].
Although phase I trial with gefitinib plus sirolimus in
recurrent malignant gliomas was deemed safe and well-
tolerated, radiographic response was comparable to that
observed in GBM patients after temozolomide at first
recurrence [66] and progression free survival was similar
to that reported after phase II trial of gefitinib in recur-
rent GBMs [53]. Another phase I/II trial combining
everolimus with gefitinib resulted in median progression
free survival of 2.6 months and disease stabilisation for
more than 4 months in 11% of recurrent GBM patients
[67] based on radiographic response. Only one patient
was progression-free beyond 6 months. Other combina-
tions include a Raf inhibitor LBT613 (Norvartis, Basel,
Switzerland) and everolimus in blocking proliferation and
invasion of glioma cell lines [68]. A phase I/II clinical trial
(# NCT00335764) is currently recruiting recurrent GBM
patients for combined Raf and mTOR inhibition with
Sorafenib (Nexavar®, Bayer, and Onyx, Emeryville, CA,
USA), and temsirolimus (CCI-779), respectively.
Regulation of apoptosis in glioblastomas
Although much is known about the diverse genotypes
causing the heterogeneous histological phenotypes of
GBMs and how they impact on survival signalling, there
is still no therapy that induces tumour cell apoptosis
beyond that of the standard treatment. Apoptosis is a
process whereby cells undergo programmed death and is
a counterbalance to proliferation. It is morphologically
distinct from necrosis and involves shrinkage and frag-
mentation of both the nucleus and the cell without rup-
ture of the cellular membrane. This prevents
inflammation of the surrounding tissue. Apoptosis relies
on activation of distinct signalling pathways that are often
deregulated in cancer. Thus, our ability to exploit these
pathways to design more effective and non-toxic thera-
pies for GBMs is dependent on our understanding of the
mechanisms for this deregulation.
The extrinsic pathway
The TNFR family is a large family consisting of 29 trans-
membrane receptor proteins, organized in homotrimers
and activated by binding of the respective ligand(s), Fig-
ure 3. There are 19 members of the TNF ligand family
[69,70] and binding may result in a number of responses,
including proliferation, inflammation and apoptosis,
depending on the adaptor proteins associated with the
activated receptor. The receptors that mediate apoptosis
are TNF-R1, FAS and DR4/DR5, and bind TNFα, CD95
and Tumour necrosis factor-related apoptosis-inducing
ligand (TRAIL), respectively. Receptor trimerisation
results in recruitment of several death domains (DD) and
eventually recruitment and activation of caspase-8 and
caspase-10. TNFR may also stimulate pro inflammatory
Figure 3 Apoptosis Signalling network. The extrinsic apoptosis 
pathway is activated upon ligand binding to death receptors (TNFR1, 
Fas/CD95, DR4/5). This results in activation of a caspase cascade and 
eventually cleavage of both cytoplasmic and nuclear substrates. 
TNFR1 may promote survival signalling through activation of NFκB. 
The intrinsic pathway involves release of apoptotic proteins from the 
mitochondria, formation of the apoptosome and subsequently cas-
pase activation. Members of the BCL-2 protein family are involved in 
regulation of the intrinsic apoptotic pathway. The extrinsic and the in-
trinsic pathways converge in a caspase cascade that results in cellular 
shrinkage, DNA fragmentation and eventually apoptosis. These path-
ways are highly deregulated in GBMs. Tumour necrosis factor receptor 
(TNFR), Tumour necrosis related apoptosis-inducing ligand (TRAIL), 
TNFR type 1-associated death domain protein (TRADD), Death recep-
tor (DR), Fas-associated protein with death domain (FADD), TNFR asso-
ciated factor (TRAF), Receptor interacting protein (RIP), FLICE-like 
inhibitory protein (FLIP), X-linked inhibitor of apoptosis protein (XIAP), 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), 
Inhibitor of κB (IκB), IκB kinases (IKKs), cytochrome c (Cyt c), Apoptotic 
protease activating factor 1 (Apaf-1).
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of RIP. Activation of the caspase cascade results in the
cleavage of target substrates by effector caspases [71] and
activation of the intrinsic signalling pathway, thereby
linking this to the extrinsic pathway. Activation of cas-
pase-8 may be prevented by FLICE inhibitory protein
(FLIP).
The intrinsic pathway
The intrinsic pathway is triggered by signals such as DNA
damage, oxidative stress or growth factor deprivation.
Upon activation by death signals, the pro-apoptotic B-cell
lymphoma 2 (BCL-2) members BAX and BAK undergo
conformational change and insert into the outer mito-
chondrial membrane. This increases the membrane per-
meability by forming and/or regulating membrane
channels that allow release of cytochrome c [72]. Cyto-
plasmic cytochrome c binds Apaf-1 and facilitates the
recruitment of caspase-9 and assembly into an apopto-
some along with ATP. This results in caspase-9 auto-acti-
vation and subsequent activation of caspase-3 and
downstream cascades.
Under conditions that favour cell survival, anti-apop-
totic BCL-2 family members, such as BCL-2 and BCL-XL
bind and inhibit pro-apoptotic BCL-2 proteins BAX and
BAK, thereby inhibiting the intrinsic apoptosis pathway.
BCL-2 family proteins share BCL-2 homology domains
(BH1-4) and form homo- and heterodimers. The expres-
sion level of BCL-2 proteins is controlled by transcrip-
tional activation by several factors, including P53. The
level of pro- versus anti-apoptotic BCL-2 proteins plays a
critical role in regulating the apoptotic process [73]. Up-
regulation of the pro-survival proteins BCL-2 and BCL-
XL, but down-regulation of BAX has been described in
recurrent GBMs independent of treatment [74]. This
indicates that untreated GBMs are subjected to pressure
for development of apoptosis resistance and that this
might be a natural course of the disease. Not surprisingly,
in a microarray study of 20 patient GBM biopsies, Ruano
et al found that several apoptosis related genes were dys-
regulated. The authors also investigated the significance
of expression-levels of the pro-apoptotic protein BAX
and found that negative expression of BAX correlated
with an adverse clinical outcome [75]. Overexpression of
BCL-2 or BCL-XL not only leads to resistance to apopto-
sis but has also been linked to increased tumour cell
motility [76].
The anti-apoptotic protein BCL-2L12 is a multifunc-
tional protein that is overexpressed in nearly all GBMs
[77]. Overexpression leads to disregulation of apoptosis
at the post-mitochondrial level through inhibition of cas-
pase activation [78]. In their system, BCL-2L12 overex-
pression resulted in expression of αB-crystallin, which
directly binds and inhibits caspase-3. Blocking the BCL-
2L12/αB-crystallin action on effector caspases might
enhance GBM responsiveness to pro-apoptotic agents
such as chemo- and radiation therapy.
Targeting the apoptotic machinery in GBMs
Human glioma cell lines express both pro- and anti-apop-
totic BCL-2 proteins [79], members of the TNFR super
family and their ligands, such as TNFR and TNFα [80],
FasR and CD95/FasL [81], DR5 and TRAIL [82]. Manipu-
lation of these has been shown to affect the cells ability to
undergo apoptosis. However, much of our knowledge on
apoptosis deregulation in GBM relies on studies using in
vitro cell cultures. The relevance of the findings has been
debated since long-term cell lines do not represent the
heterogeneous nature of the disease. In addition, GBMs
in vivo are subjected to different selection pressures com-
pared to cells in culture, resulting in both different geno-
types and phenotypes. Nevertheless, our increasing
knowledge on apoptosis signalling in general might pro-
vide new strategies to improve treatment of GBM.
The BCL-2 proteins
Several therapeutic agents that target members of the
BCL-2 family have been developed and many of these
have been tested in preclinical or clinical trials [83,84].
However, only few have been tested on glioblastomas,
and only one compound has reached clinical trials with
GBM patients. BCL-2 inhibitors may overcome drug
resistance in human tumours that overexpress anti-apop-
totic BCL-2 and BCL-XL proteins. The BCL-2 inhibitor,
ABT-737, was recently shown to induce apoptosis in glio-
blastoma cells both in vitro and in vivo by releasing the
pro-apoptotic BAX protein from its binding partner
BCL-2 [85]. ABT-373 sensitized cells to both anti-cancer
drugs and to the death ligand TRAIL. However, the effect
of ABT-737 was less efficient in cells with high expression
of the BCL-2 family protein MCL-1 and the authors sug-
gest that downregulation of MCL-1 might be used in
combination with ABT-737 as a novel approach. The
BH3-binding compound HA14-1 has also been reported
to increase sensitivity of human glioblastoma cells to both
radio- and chemotherapy [86]. However, so far the only
BCL-2 targeting compound tested in clinical trials for
treatment of GBMs is the multi-targeting compound
Gossypol. Gossypol is a polyphenol derived from the cot-
ton plant and was tested on patients with recurrent
malignant gliomas in early clinical trials [87]. Administra-
tion of Gossypol 20 mg/day was well tolerated, and had a
low but measurable response rate. Later, it was found that
Gossypol binds to the BH3 pocket of anti-apoptotic BCL-
2 proteins [88,89], as well as other target proteins (for a
review on biological activity of Gossypol, see [90]). A
phase II study of Gossypol (AT-101) in recurrent GBM is
currently ongoing to determine the acute and late toxicity
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(NCT00540722). In addition, a phase I trial to investigate
the side effects and dosage of Gossypol in combination
with temozolomide with or without radiation in patients
newly diagnosed with GBM (NCT00390403) has recently
been completed (June 2009). Results from this trial have
not yet been published and are eagerly awaited as they
might reveal whether the use of BCL-2 antagonists pro-
vides better survival for GBM patients.
P53 as a therapy target
The role of P53 is closely related to that of the BCL-2 pro-
teins. P53 promotes apoptosis following DNA damage
[91] and has a well characterised role as a transcription
factor. Direct transcription targets of P53 include
pro-apoptotic members of the BCL-2 family such as BAX,
BIM, the BH3-only proteins PUMA and NOXA. In addi-
tion, a cytoplasmic function of P53 that is independent of
its transcriptional activity has been demonstrated in the
regulation of mitochondrial membrane permeabilisation.
Cytoplasmic P53 can function as a pro-apoptotic BH3-
domain protein that leads to the release of cytochrome c
from the mitochondria, induction of caspases and cell
death [92]. TP53 is mutated in most human cancers, and
loss-of-function leads to deregulation of apoptosis signal-
ling and increased tumourigenesis. Indeed, P53 pathway
alteration was recently reported in 87% of GBMs and sug-
gested to be a core requirement for GBM pathogenesis
[24]. Several clinical trials targeting P53 have been con-
ducted. Two phase I gene therapy trials using adenovirus-
TP53 to re-introduce a functional TP53 gene have been
completed (NCT00004080 and NCT00004041), (Febru-
ary 2009) but not yet published. The objectives were to
determine toxicity of the adenovirus, transduction effi-
ciency and effect on disease progression.
TNFR super family and their ligands
At present, anti-tumour strategies using recombinant
human TNFα (rhTNFα) or agonistic CD95 antibody are
limited to local delivery to avoid systemic side effects
[93,94]. Even though some toxicity problems occurred in
early preclinical trials with TRAIL, more recent preclini-
cal and clinical trials showed that soluble recombinant
human TRAIL (rhTRAIL) and TRAIL antagonistic anti-
bodies are non-toxic and raise the expectations of TRAIL
as an amenable therapeutic approach. TRAIL is a type II
transmembrane protein that was identified and cloned
based on sequence homology to CD95 and TNF [95,96].
It interacts with two pro-apoptotic death receptors, DR5
and DR4 and two decoy receptors (DcR1 and DcR2)
[97,98]. TRAIL selectively induces apoptosis in cancer
cells, both in vitro and in vivo and has little or no toxicity
in normal cells [99-101]. Most glioblastoma cell lines
express DR5 and DR4 that transduce the apoptotic signal
via the death domains, but far fewer express the decoy
receptors [79]. rhTRAIL and its DR5 agonistic antibody
TRA-8 induce apoptosis in glioblastoma cell lines, [102-
105], and intracranial delivery of native human TRAIL
suppresses the growth of human glioma xenografts in
mice without host toxicity [106,107]. However a majority
of glioblastoma cells are resistant to TRAIL despite
expressing DR5 and DR4, indicating that the resistance
mechanisms might involve defects downstream of the
receptor. Thus, one strategy for sensitizing GBMs to
TRAIL has been to target the signalling pathway down-
stream of TRAIL through targeting of c-FLIP, BCL-2 and
XIAP (Figure 3). Several recent studies have pointed to
the use of TRAIL in combination therapy. The use of
mTOR inhibitors like rapamycin in combination with
TRAIL [108] has been suggested to inhibit the activity of
FLIP(S) and thereby allowing activation of caspase-8
[109]. TRAIL has also been administered in combination
with temozolomide in preclinical studies, where systemic
injection increases survival of xenografted mice [107]. In
tumours were the TRAIL signalling pathway is intact,
combination treatment of TRAIL with radiation and
temozolomide might be a possible therapeutic approach.
Treatment with rhTRAIL and radiation upregulates cas-
pase-8 [110] and DR5 [111], while radiation combined
with TRA-8 antibody increases survival of mice with glio-
blastoma xenografts [111].
Several reports have indicated a novel role of CD95,
where it has emerged as an important modulator of the
MAPK pathway [112] as well as the transcription factor
NFκB [113,114]. A recent report showed that GBM
tumours are resistant to CD95-induced apoptosis and
that CD95 stimulation instead increase their invasion
capacity [115]. Thus, targeting CD95 might inhibit
tumour migration and further sensitize the tumours to
the standard therapy.
Targeting Inhibitor of Apoptosis Proteins (IAPs)
IAP-family proteins include X-linked inhibitor of apopto-
sis (XIAP), cIAP1, cIAP2, ILP2, ML-IAP, NAIP, SUR-
VIVIN and BRUCE [116-118]. They inhibit apoptosis by
binding to caspase-9 in the intrinsic pathway and also the
downstream effector caspase-3 and caspase-7. IAPs such
as XIAP are highly expressed in malignant gliomas, and
they have been associated with refractory disease and
poor prognosis [116,119]. Targeting of IAPs to release the
caspases to induce apoptosis has been a popular
approach in drug design and several IAP-directed agents
are in preclinical trials [120,121]. However, little has been
done with regard to GBMs and IAPs. It is clear from
GBM cell line studies that targeting of IAPs sensitizes
cells to apoptosis [122,123] and a recent report showed
that XIAP inhibitors synergizes with radiation to increase
glioblastoma cell apoptosis [124]. Targeting of IAPs also
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transfer of the IAP-inhibitor second mitochondria-
derived activator of caspase (SMAC) peptides strongly
enhanced the anti-tumour activity of TRAIL in an intrac-
ranial malignant glioma xenograft model [7]. Other clini-
cal trials targeting specific, but poorly characterized
aspects of apoptosis are at the moment ongoing, includ-
ing administration of histone deacetylase (trial #
NCT00313664, NCT00313664) and proteosome inhibi-
tors (NCT01020292, NCT00915694; http://www.clinical-
trial.gov).
The biophysical challenges to the successful 
treatment of GBM
Diffuse invasion, chaotic and stagnant blood flow
GBMs are denoted by diffuse invasion of the brain paren-
chyma by single cells trans corpus callosum to form the
characteristic "butterfly" GBM. Invading glioma cells
transiently arrest from mitosis [125,126] and may thus be
refractory from DNA damaging agents such as chemo-
therapy and radiotherapy. Nevertheless, the morbidity
and mortality from GBM stems from local invasion that
invariably limits complete surgical resection. This results
in recurrence within 2 cm of the original surgical margin
in 80-90% of GBM patients [127]. Thus, in addition to
achieving local control, novel therapies must act on cells
disseminated into the normal brain. The cells invading
the relatively normal parenchyma are often protected by
an intact BBB. The passage of therapeutic agents from the
circulation through the BBB favours small, uncharged
lipid soluble molecules. Although GBMs are highly vas-
cular, the BBB of the gross tumour is variably disrupted,
exhibiting breaks in tight junctions, increased pinocyto-
sis, fenestrations, permeability (partially due to upregu-
lated VEGF and aquaporin-4) and decreased pericyte
coverage [128]. The leaky vessels give rise to stagnant
blood flow, oedema, high interstitial fluid pressure gradi-
ents that result in capillary and venous collapse that fur-
ther forms obstacles for drug penetration. Convection
enhanced delivery (CED) has emerged as the drug-deliv-
ery method of choice for effective delivery of large and
small substances to the brain where the therapeutic agent
is infused at high pressure and is dependent on bulk flow
[129].
GBM cancer stem cells
Cancer stem cells (CSCs) have been described within
solid tumours, including GBMs [130] as small popula-
tions of cells possessing neural stem cell markers, limited
differentiation capacity and the ability to clonally self-
renew into neurospheres and secondary tumours that
retain the histological features of the primary tumours.
Several studies proclaimed that brain tumours enriched
in CSCs were preferentially resistant to ionising radiation
and chemotherapy due to altered checkpoint and DNA
repair pathways compared to conventional tumour cells
[131-133]. Others have claimed that these cells are associ-
ated with increased reactive oxygen species [134] and
that this is an additional mechanism for radiation resis-
tance [135]. It has also been shown that brain CSCs may
be preferentially sensitive to AKT inhibitors [136]. The
question has thus been raised whether the current thera-
peutic strategies are targeting the right tumour cell popu-
lations. Protocols that target rapidly dividing cells will
invariably target the bulk tumour cells, leaving behind the
slow cycling, resistant CSC clones capable of repopulat-
ing the tumour.
Conclusion
Despite the great excitement over potential benefits of
targeting the PI3K pathway alone or in combination with
inhibitors of the EGFR or mTOR pathways, the likelihood
of achieving long-lasting therapeutic benefits for patients
with recurrent GBM remains uncertain. So far targeting
this survival signalling circuitry has mainly resulted in
tumour growth stasis and limited cellular cytotoxicity. In
addition to targeting key members of the survival signal-
ling machinery, combination therapies should perhaps
include members of the apoptosis network that might
execute the death signal. However, to date, very few clini-
cal trials exploit our knowledge on apoptosis signalling in
regard to treatment of GBM patients. This is possibly due
to the complex heterogeneity that exists within GBMs,
issues with blood brain barrier penetrance, and economic
constraints. With an incidence of 6-7/100 000 new cases,
GBMs belong to a group of orphan diseases that may pro-
vide little financial incentive to the pharmaceutical com-
panies. The future direction is to optimise surgical
management for maximal tumour de-bulking and design
of synergistic multi-target drug combinations. They
should include chemotherapy, radiotherapy, targeting the
apoptosis and cell survival regulatory machinery. The
only challenge is that with all the possible target combi-
nations, we may not have time to test all potential candi-
dates by the sequential phase I, II and III trial design. In
addition, the plethora of possible combinations might be
insurmountable and exhibit unknown toxicity profiles.
However, making multiple small advances in the manage-
ment of these lethal cancers will ultimately result in big
progress.
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